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Objective: The aim of this study was to determine various
types of contraindicated medications that are adminis-
tered to patients with renal insufficiency by physicians
who override alerts provided by the Computerized De-
cision Support Systems (CDSS).
Methods: This retrospective study incorporated all
admitted patients during the period from January 1st
through December 31st, 2010, with serum creatinine
levels >1.7 mg/dL in a major tertiary hospital in the
Eastern Province of the Kingdom of Saudi Arabia
(KSA). Chi-square and multivariate logistic regression
tests were used to evaluate the factors associated with
the increased likelihood of patients receiving contra-
indicated medication due to physicians overriding the
CDSS alert.
Results: A total of 314 patients received at least one
medication that was renally cleared and/or potentially
nephrotoxic. Fourteen percent of these medications were
contraindicated and resulted in a system alert and yet
were administered to the patients. The administeredy. This is an open access article under the CC BY-NC-ND license
.1016/j.jtumed.2015.02.012
A. Youssef et al. 321contraindicated medications were limited to 4 drugs:
aspirin, gliclazide, nitrofurantoin, and spironolactone,
with aspirin accounting for approximately 60% of all of
the medications received by patients. Multivariate logistic
regression showed that the odds of receiving these four
contraindicated drugs increased in those with severe renal
insufficiency (OR ¼ 23.4, 95% CI 9.9e54.9, p < 0.001)
after adjusting for confounding factors.
Conclusion: Physicians override the CDSS alerts and
prescribe medications that are contraindicated for pa-
tients with renal impairment. These medications are
limited in number. This study also emphasizes that the
medication database system might need to be updated
with input from the physicians using the system.
Keywords: Alert; Clinical decision support system; Contra-
indicated medications; Override; Renal insufficiency
 2015 The Authors.
Production and hosting by Elsevier Ltd on behalf of Taibah
University. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).Introduction
The high prevalence of renal insufficiency in hospital
populations and the fact that most drugs and their active
metabolites are eliminated through the kidney makes this
group of patients highly vulnerable for adverse drug events.1
Physicians need to consider adjusting the dosage to the level
of renal function when prescribing medications to avoid an
over dosage, toxicity or further worsening of renal
function. With the large number of drugs introduced each
year that have varying relationships with the function of
the kidney, it is hard for any physician to accurately recall
these relations from memory. It is no surprise that several
studies have demonstrated high rates of inappropriate
dosing for patients with renal insufficiency.2e4 In a large
case-control study, Chertow et al. revealed that the inap-
propriate prescription of nephrotoxic or renally cleared
medications occurred at a rate of 70% in patients hospital-
ized with renal impairment.5 In another study, the authors
indicated that among 1648 patients, 67% of the drugs
prescribed were not adjusted to individual renal function
levels.6 To address this problem, the Institute of Medicine
and other influential organizations have endorsed clinical
decision support systems (CDSS) as an important strategy
for reducing medication errors.7
In Saudi Arabia, just as in other parts of the world, medi-
cation error is a major concern. Khoja et al. found that 18.7%
of all of the prescriptions in an inpatient setting aremedication
errors.8 In a paediatric setting, Al- Jeraisy et al. found that
overall medication errors were present in 56 per 100
medication orders.9 Even though reducing medication error
is important for all of the patients receiving medical care,
patients with renal insufficiency are of particular importance.
Not only are they at an increased risk of medication errors
and adverse drug events but also the prevalence of chronickidney disease (CKD) in the Kingdom has been increasing at
a fast rate over the last three decades as a result of social and
demographic changes.10,11
With the mandatory introduction of hospital information
systems by the Saudi Ministry of Health, integrating CDSS
with the Computerized Physician Order Entry (CPOE) can
advise physicians on appropriate dosing for patients at
varying levels of renal function at the point of care.12
However, a number of studies have shown that CDSS had
limited success in reducing medication errors.13e15 The
most cited explanation was clinician noncompliance with
the alert or advice provided by these systems.16,17
Frequent clinically unjustified alerts presented to physicians
as they enter their drug orders may result in what has been
termed “alert fatigue”, whichmay cause physicians to override
clinically important alerts or to even totally abandon the
decision support system.18,19 However, at the same time,
medications that result in such alerts are considered by the
CDSS knowledge base to be of high risk and are harmful
to patients with a compromised kidney reserve. Insight into
the medications to which physicians tend to override
contraindications may reveal potential problems in the
CDSS knowledge database that need to be updated or a lack
of knowledge of the medication risks risk by treating
physicians that may require more physician training. To
better understand these issues, this study aimed to determine
the types of contraindicated medications administered to
patients with renal insufficiency by physicians who override
CDSS alerts in a major Ministry of Health hospital in Saudi




This study was conducted in a major Ministry of Health
referral hospital providing tertiary care in the Eastern
Province, Saudi Arabia. This 600-bed hospital utilizes a
commercial electronic medical record (EMR) supported by
CDSS that was mandated by the Ministry of Health. This
system supports all orders, laboratory results, and patient
medication information in the hospital. Computerized order
checking for patient-specific parameters with decision sup-
port algorithms, including drugedrug interaction, allergies,
and drug lab and drug disease interactions, are fully func-
tional. In addition, the system provides advice alerts on drug
dosing and avoidance. This study was approved by the
Hospital Institutional Review Board.
CDSS and internal logic relevant to renal insufficiency
Each time a newly measured serum creatinine is added by
the Lab in the EMR, an estimated creatinine clearance
(eCrCl) is calculated according to CockcrofteGault (CG)
equation.20 Utilizing a list of drugs that are either renally
cleared and/or are potentially nephrotoxic, the internal
logic of the commercial CDSS was designed to trigger an
avoid alert if the physician attempts to order one of the
contraindicated drugs according to the most recently
calculated eCrCl and predetermined safe cut-off point for
Decision support and contraindicated medication322the drug. The system provides a screen alert message and the
established recommendations for completing the order.
Data source
During the one-year period (from January 1st through
December 31st, 2009), patients with serum creatinine levels
>1.7 mg/dL were candidates to be included in the study.
Detailed prescriptions, age, sex, serum creatinine, body
weight, and type of treating physician (specialist: yes/no) were
abstracted from the electronic medical record. A detailed
examination of the data was performed for medications that
are renally cleared and/or potentially nephrotoxic. The most
recent documented values for weight, serum creatinine and
eGFR prior to each prescription of a medication that was
renally cleared and/or potentially nephrotoxic were used to
estimate kidney function just prior to the prescription of such
medication. These medications were then categorized ac-
cording to the CDSS internal database into two types: 1)
contraindicated medications, if the administered medication
was considered to be contraindicated given the kidney func-
tion just prior to its administration (irrespective to the drug
type or group); 2) not a contraindicated medication, if the
medication was renally cleared and/or nephrotoxic but not
contraindicated given the level of renal function just prior to
its administration. Patients <18 years and those who had a
renal transplant, were on dialysis, or were diagnosed with
acute kidney injury (AKI) were excluded from the study.
Estimation of kidney function
Renal function in adults is usually reported on the basis of
eGFR normalized to a body surface area of 1.73 m2 and
derived from the Modification of Diet in Renal Disease
(MDRD) formula. However, published information on the
effects of renal insufficiency on drug elimination is usually
stated in terms of eCrCl as a surrogate for the glomerular
filtration rate. For potentially toxic drugs, the eCrCl calcu-
lated from the CG formula is used to adjust the dosages.20
The National Kidney Disease Education Program
(NDKEP) in the US recommends that the GFR estimated
from the MDRD study or eCrCl estimates from the CG
equations for adults can be used for drug dosing.21
For this study, the two methods used to calculate esti-
mated kidney function were the CockcrofteGault equation20
and the abbreviated MDRD study equation.22
CockcroftGault creatinine clearnace ðmL=minÞ
¼
ð140 ageÞ½lean body weightðkgÞC
½serum creatinie ðmmol=LÞ
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*ðageÞ0:203*ð0:742 if femaleÞ*ð1:212 if blackÞStatistical analysis
We first described the study population with the means
and standard deviations for continuous variables and pro-
portions for categorical variables. Fisher’s exact test was
used for univariate analysis followed by multivariate logistic
regression (enter method) to determine the physician and
patient characteristics associated with ordering contra-
indicated medications. The dependent variable was the
admission of a contraindicated medication (yes/no). The
independent variables included patient age, sex, severity of
renal insufficiency (sever vs. mild/moderate), shift during
which the prescription was given (8 ame4 pm/4p me8 am)
and day that the prescription was given (weekend/weekday).
The physician specialist status (specialist/not specialist) was
also included. All analyses were performed using STATA
v.11 (Stata Corp, College Station, Texas).Results
Out of the 314 prescriptions that were renally cleared and/
or potentially nephrotoxic, 44 (14%) were for contra-
indicated medications. The mean (SD) age of this study
group was 54.5 (18.6) years, 55.4% were male, 18.5% had
severe renal insufficiency, and approximately 83% of the
orders were given by a non-specialist, Table 1.
Table 2 demonstrates that the contraindicated
medications ordered were limited to only 4 types, 59.1%
(n ¼ 26) were for aspirin, 29.6% (n ¼ 13) were for
gliclazide, and 9.1% (n ¼ 4) were for nitrofurantoin; and
only one patient received spironolactone.
Table 3 presents the patient characteristics according to
whether they received one of the four contraindicated
medications. Of the patients who received a
contraindicated medication, 56.8% (n ¼ 25) were given to
patients aged >65 years compared to 28.2% (n ¼ 76)
among patients who did not receive a contraindicated
medication, P ¼ 0.001. A high percentage of patients who
received contraindicated medications were patients with
severe renal insufficiency, 70.5% (n ¼ 31) compared to
only 10% (n ¼ 27) among those who were not given a
contraindicated medication, P < 0.001.
Table 4 presents the results of the multivariate logistic
regression confirming that after adjusting for all of the
confounding factors, patients with severe renal
insufficiency were more likely to receive one of the four
contraindicated medications despite the alert compared to
patients with a milder renal insufficiency (OR 23.4, 95% CI
9.9e54.9; P < 0.001).Discussion
In this study, 314 patients with serum creatinine >1.7 mg/
dL received at least one medication that was renally cleared
and/or potentially nephrotoxic. Fourteen percent of those
were for contraindicated medications that resulted in a sys-
tem alert and were still administered to the patients by the
ordering physician despite the alert. Administered contra-
indicated medications included 4 drugs: aspirin, gliclazide,

















Female 23(52.3) 117(43.3) 0.27
Day of the week
Weekday 39(88.6) 215(79.6)
Weekend 5(11.4) 55(20.4) 0.16
Shift of the day
8 ame4 pm 25(56.8) 177(65.6)
4 pm 8 am 19(43.2) 93(34.4) 0.41











Yes 12(27.3) 42(15.6) 0.07
a Severe renal insufficiency is 10 mL/min; mild/moderate
renal insufficiency is 11e50 mL/min.












Sever renal insufficiency 58 18.5
Mild/Moderate renal insufficiency 256 81.5
Day timec
8 ame4 pm 203 64.6
5 pme7 am 111 35.4
Day of the week







Not contraindicated 270 86.0
a The number is the mean and standard deviation.
b Severe renal insufficiency is  10 mL/min; mild/moderate
renal insufficiency is 11e50 mL/min.
c Day time: the time of day the order was entered.
d Contraindicated: physician ordered a contraindicated medi-
cation; not contraindicated: physician ordered a medication that
was not contraindicated and did not produce an avoid alert.
Table 4: Multivariate logistic regression for the factors asso-
ciated with the increased likelihood of receiving one of the four
contraindicated medications.
Characteristics ORa 95% CI P-value
Age
18e <55 1
55e < 65 1.9 0.5e7.1 0.34
65 6.1 2.4e15.4 <0.001
Level of renal insufficiencyb
Mild/moderate renal insufficiency 1
Sever renal insufficiency 23.4 9.9e54.9 <0.001
Gender
Male 1
A. Youssef et al. 323nitrofurantoin, and spironolactone with aspirin, which
accounted for approximately 60% of these medications.
Several studies on the effectiveness of CDSS alerts to
reduce the prescription of the contraindicated medications to
patients with a renal insufficiency found a wide range of
effectiveness of alerts by these systems, with most of these
studies finding reduced levels of effectiveness, mostly due to
noncompliance by physicians.5,23e25 In our study, and
similar to other studies, the administration of
contraindicated medications to patients with renal
insufficiency is still high in hospitals that implemented
CDSS, although it is lower compared to previous studies:
14% in our study vs. a range of 19.9%e47% among other
studies.17,26,27 There are three main explanations for the
discrepancy between our study and the previous studies.
First, a variation in the definition of error could explain
this difference. In our study, error was defined asTable 2: Administered contraindicated medications according




10 11e50 Male Female Mean (SD)
Aspirin 26 (59.1) 26 0 12 14 60.1 (22.4)
Gliclazide 13 (29.6) 4 9 6 7 62.4 (16.7)
Nitrofurantoin 4 (9.1) 0 4 3 1 78.7 (4.2)
Spironolactone 1 (2.2) 1 0 0 1 48 (0)
Female 1.3 0.6e2.9 0.51
Day time
8 ame4 pm 1
5 pme7 am 1.4 0.6e3.2 0.41
Day of the week
Week days 1
Weekends 0.5 0.2e1.7 0.28
Consultant
No 1
Yes 2.26 0.9e5.9 0.10
a OR¼Odds ratio.
b Severe renal insufficiency is 10 mL/min; mild/moderate
renal insufficiency is 11e50 mL/min.
Decision support and contraindicated medication324administering drugs that are contraindicated given the level
of renal impairment, while other studies defined error as a
combination of the administration of contraindicated drugs
and/or the administration of an inappropriate dose.
Second, there are major variations in the drug information
sources used by the systems in these different studies.28
Some drugs that are marked as contraindicated in one
source are not considered to be such in another source.
Third, there are variations in the definition and
classification of renal impairment among these sources;
some sources categorized renal function into five different
stages,29 while others divided renal function into three
categories, which leads to some drugs being considered to
be contraindicated in some studies but not in others.30
In a study by Salomon et al.,31 in a setting with no CDSS
system, the authors found that among 886 prescriptions
that were four drugs that were either renally cleared and/or
potentially nephrotoxic, 14% received contraindicated
medications, which is similar to the percentage in our study
hospital with a fully functioning CDSS system. This might
indicate that physicians in our study hospital were
noncompliant to the system alerts. Our study did not
interview physicians to determine their reasons for
noncompliance with the decision support recommendations.
However, some of the causes for noncompliance have been
examined in previous studies.32e34 One proposed cause is
that CDSS systems provide alerts for reordering or
renewing medication orders that were previously tolerated
by the patient.33 Noncompliance can also result when the
physician feels that he/she knows more about the specific
clinical condition of the patient than the CDSS. Physicians
often see their patients on a daily basis and are likely to be
familiar with changes in their medical condition. This level
of information may not be available to the CDSS or may be
in a format that cannot be utilized by the logic of the
system.34 Another factor that was suggested is the clinical
usefulness of the alert itself. Spina et al.32 found that 86%
of the alerts were actually not useful. On the other hand, it
is also possible that noncompliance could be caused by a
lack of knowledge among physicians about the necessity of
withholding such medications in patients with a renal
insufficiency.23
In our study,most of the overridden orderswere for aspirin.
Other overridden orders were for nitrofurantoin, gliclazide,
and spironolactone. Interestingly, the chronic effects of these
medications on the progression of renal insufficiency, as pre-
sented in the literature, are contradicting and inconclusive at
best. For example, the BNF indicates that aspirin should be
used with caution and should to be avoided in cases of severe
renal impairment.35 Others have also indicated that aspirin has
exacerbating effects in patients with CKD in a dose-dependent
manner.36 That is in contrast to other studies that indicated
that aspirin might be safe for use in patients with diagnosed
advanced renal insufficiency stages 4e5 without an adverse
effect on the progression of the disease.37 BNF indicated that
nitrofurantoin should be avoided altogether if the eGFR is
less than 60 mL/min.35 Furthermore, nitrofurantion product
information also indicated that it is contraindicated in
patients with eCrCl values below 60 ml/min.38 In contrast,
the literature review by Oplinger et al. indicated that the data
supporting the contraindication of nitrofurantoin for
patients with eCrCl values less than 60 mL/min arenonexistent.39 Gliclazide, like other sulfonylureas, has
increased potency as the renal function decreases and is
considered in some literature to be contraindicated in severe
renal failure.40 Other recent studies, however, indicated that
it is a preferred sulfonylurea with no need for dose
adjustment.41 Finally, spironolactone is considered by some
published studies to be well tolerated in select patients with
early stage renal insufficiency, although strict monitoring
over the first few months is suggested.42
Given this inconsistency, it is possible that the physicians
in this study hospital are not only accustomed to and
frequently use these medications in everyday practice but are
also familiar with the indecisiveness about the effect of these
medications in the medical community. It is no surprise that
many physician override the avoid alert when they try to
administer these drugs to their patients.
Our study investigated the factors that are associated with
noncompliance and the eventual receipt of one of these four
contraindicated medications. Older people were at a higher
risk for receiving these contraindicated medications. We also
found a surprising negative association between noncom-
pliance with these medications and the level of renal
dysfunction. Salomon et al.31 suggested that this unexpected
pattern does not reflect the quality of the physician order but
the fact that the same medication order that is considered to
be contraindicated in patients with severe renal insufficiency
is considered to be appropriate in patients with mild/
moderate renal insufficiency. We believe that more studies
are needed to verify Salomon’s argument.
There are several limitations of the current study. First,
the study was conducted in only one Ministry of Health
affiliated hospital using a commercial CDSS system.
Accordingly, the results may not be generalizable to other
hospitals or other systems. Second, this study did not
examine the adverse effects on the involved patients; there-
fore, we do not know what harmful effect, if any, the over-
ridden alerts had on these patients. Third, the unavailability
of the data on the demographic characteristics of both the
patients and treating physicians, other comorbidities, and
main underlining disease of the patient is another limitation
of the study. Including these factors in our analysis would
have better explained the different reasons that physicians
override alerts.Conclusion
Our study has two main conclusions. First, physicians
override the CDSS alerts and prescribe medications that are
considered to be contraindicated by the CDSS knowledge
database for patients with reduced renal function. Second,
these medications are limited in number, and thus, physicians
could be encouraged to replace these medications with other
safer medications or at least be educated about the contra-
indications. More studies are needed to determine physi-
cians’ perceptions about the system and the factors related to
their noncompliance to its alerts. More studies are also
needed to evaluate the system information, system integra-
tion, and its alliance with the organizational and clinical
workflow.
The paucity of these types of studies in Saudi Arabia
makes this study of great importance and an incentive for
A. Youssef et al. 325future studies, particularly as the Saudi government is
moving forward with implementing these systems in hospi-
tals nationwide. Decision makers need to realize that such
research must guide the development of new hospital infor-
mation technology, particularly in relation to the selection of
future systems and their flexibility to be adjusted to accom-
modate physicians’ experience and evidence based medicine.
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